Kaiser Family Foundation. Copyright 2009 Advisory Board Kaiser and Company Family Foundation. All rights reserved.. PRESS RELEASE NEW YORK—-Bristol-Myers Squibb Business today announced that it has finished the previously announced planned acquisition of Flexus Biosciences, Inc. The deal includes full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND submitting in the next half of 2015 and an IDO/TDO discovery plan which includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A recently formed entity set up by the existing shareholders of Flexus will preserve, from and after the closing, all non-IDO/TDO assets of Flexus including those linked to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancers immunotherapy programs, and its current facilities and employees.Skin checks for malignancy are normal requests for GPs and dermatologists, as are requests to eliminate benign skin damage for cosmetic factors or because they’re itchy, catching on clothing or prone to being cut. A general examination offers a good opportunity to recognize a person at risk for malignancy by observing whether she or he has sun damaged skin, a higher mole count, dysplastic naevi or additional indicators. A skin check is a period consuming process; it should not be done on the fly preferably. People with risk factors for skin cancers should see their doctor for regular epidermis checks.